SG11201909615YA - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same - Google Patents

Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Info

Publication number
SG11201909615YA
SG11201909615YA SG11201909615YA SG11201909615YA SG 11201909615Y A SG11201909615Y A SG 11201909615YA SG 11201909615Y A SG11201909615Y A SG 11201909615YA SG 11201909615Y A SG11201909615Y A SG 11201909615YA
Authority
SG
Singapore
Prior art keywords
gyeonggi
gil
international
preparing
crystalline form
Prior art date
Application number
Other languages
English (en)
Inventor
Sang Ho Oh
Jong Gyun Kim
Se-Woong Oh
Tae Dong Han
Soo Yong Chung
Seong Ran Lee
Kyeong Bae Kim
Young Sung Lee
Woo Seob Shin
Hyun Ju
Jeong Ki Kang
Su Min Park
Dong Kyun Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909615Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of SG11201909615YA publication Critical patent/SG11201909615YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201909615Y 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same SG11201909615YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Publications (1)

Publication Number Publication Date
SG11201909615YA true SG11201909615YA (en) 2019-11-28

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909615Y SG11201909615YA (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Country Status (22)

Country Link
US (3) US11453656B2 (enExample)
EP (1) EP3612529A4 (enExample)
JP (2) JP7126514B2 (enExample)
KR (3) KR102629654B1 (enExample)
CN (1) CN110869367B (enExample)
AR (1) AR111469A1 (enExample)
AU (2) AU2018256227B2 (enExample)
CA (1) CA3059543A1 (enExample)
CO (1) CO2019011578A2 (enExample)
EA (1) EA201992501A1 (enExample)
IL (2) IL294666B2 (enExample)
MA (1) MA49696A (enExample)
MX (2) MX392634B (enExample)
MY (1) MY201919A (enExample)
NZ (1) NZ758443A (enExample)
PH (1) PH12019502370A1 (enExample)
SA (1) SA519410342B1 (enExample)
SG (1) SG11201909615YA (enExample)
TW (1) TWI776882B (enExample)
UA (1) UA124364C2 (enExample)
WO (1) WO2018194356A1 (enExample)
ZA (1) ZA201907687B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
CN111349084B (zh) * 2018-12-21 2022-11-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
BR112021022828A2 (pt) * 2019-05-14 2022-04-12 Janssen Biotech Inc Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
EP4349835A4 (en) * 2021-06-01 2025-06-25 Hangzhou Solipharma Co., Ltd. Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Also Published As

Publication number Publication date
US20230021395A1 (en) 2023-01-26
KR20230175161A (ko) 2023-12-29
KR20180118535A (ko) 2018-10-31
US12428401B2 (en) 2025-09-30
TW201841910A (zh) 2018-12-01
SA519410342B1 (ar) 2023-02-09
US20240279203A1 (en) 2024-08-22
AU2022203486A1 (en) 2022-06-09
US20210139461A1 (en) 2021-05-13
MX392634B (es) 2025-03-24
TWI776882B (zh) 2022-09-11
IL294666B1 (en) 2024-01-01
CN110869367B (zh) 2023-09-15
MX2022006357A (es) 2022-06-23
AU2018256227A1 (en) 2019-10-31
CN110869367A (zh) 2020-03-06
IL270018A (enExample) 2019-12-31
AU2022203486B2 (en) 2024-06-06
PH12019502370A1 (en) 2020-07-13
MA49696A (fr) 2020-06-03
US11453656B2 (en) 2022-09-27
US11981659B2 (en) 2024-05-14
JP2022166179A (ja) 2022-11-01
MY201919A (en) 2024-03-23
NZ758443A (en) 2023-03-31
CO2019011578A2 (es) 2020-02-28
IL270018B (en) 2022-08-01
UA124364C2 (uk) 2021-09-01
CA3059543A1 (en) 2018-10-25
EP3612529A4 (en) 2020-11-18
EA201992501A1 (ru) 2020-02-18
JP2020517611A (ja) 2020-06-18
JP7390444B2 (ja) 2023-12-01
IL294666A (en) 2022-09-01
KR102629654B1 (ko) 2024-01-29
KR102835717B1 (ko) 2025-07-18
IL294666B2 (en) 2024-05-01
ZA201907687B (en) 2023-04-26
AU2018256227B2 (en) 2022-03-03
EP3612529A1 (en) 2020-02-26
JP7126514B2 (ja) 2022-08-26
BR112019021868A2 (pt) 2020-05-26
KR20250111074A (ko) 2025-07-22
AR111469A1 (es) 2019-07-17
WO2018194356A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908569QA (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201908235RA (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201805001UA (en) Method of treating influenza a
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201906922TA (en) Processes for preparing ag-10, its intermediates, and salts thereof
SG11201901460UA (en) Method for producing the crystalline form of modification a of calcobutrol
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201903145TA (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone